ExcitePCR's technology detects pathogens in 30 minutes or less using a backpack-sized device, integrating sample prep with PCR and RIF technology in a disposable cartridge.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
The firm's technology, called genotyping by random amplicon sequencing, or GRAS, should improve the efficiency of identifying and selecting markers for crop improvement.
